VANCOUVER, BC — May 7, 2026 — Leads & Copy — Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE.F) announced that its Chief Executive Officer, Dr. Frederick D. Sancilio, will attend the D. Boral Capital Global Conference on May 7, 2026, at The Plaza Hotel in New York City.
Lobe Sciences is a clinical-stage biopharmaceutical company advancing drug candidates through a pharmaceutical development platform, progressing assets from early development to the clinic through subsidiary companies.
Dr. Sancilio will be available for meetings with institutional investors, pharmaceutical companies, and potential strategic partners to discuss Lobe’s therapeutic programs and development strategy.
The company advances therapeutic programs addressing unmet medical needs by acquiring preclinical and early-stage assets. These assets are then advanced through focused subsidiary entities, each operating under a development and funding framework designed to achieve regulatory and clinical milestones efficiently. The model focuses on formulation development, intellectual property protection, and engagement with regulatory authorities as programs progress through key value-inflection points.
Lobe is currently advancing two patented drug product candidates through this subsidiary approach:
L-130 (psilocin mucate) is a patented, orally administered new chemical entity (NCE) designed as a stabilized form of psilocin, the active metabolite of psilocybin. The NCE aims to provide enhanced stability, improved bioavailability, and more consistent circulating levels of psilocin, supporting reliable systemic exposure compared to traditional psilocybin-based approaches. Cynaptec Pharmaceuticals, Inc., a subsidiary of Lobe with a 64% ownership interest, is conducting the development of L-130.
S-100 is an early-stage therapeutic candidate for sickle cell disease being developed through Applied Lipid Therapeutics LLC, another subsidiary of Lobe. It is designed to address underlying disease mechanisms using a lipid-based delivery platform, consisting of a blend of triglyceride esters of docosahexaenoic acid and eicosapentaenoic acid, combined with an absorption-enhancing excipient system to improve bioavailability. The company is advancing chemistry, manufacturing, and controls (CMC) activities to support clinical supply production for a planned Phase 2a study.
Organizations interested in arranging a meeting with Dr. Sancilio during the conference may contact the Company at info@lobesciences.com to schedule an appointment.
Source: Lobe Sciences Ltd.
